Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H15NO2 |
| Molecular Weight | 277.3172 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)C(C2=CC=C(O)C=C2)C3=CC=CC=N3
InChI
InChIKey=LJROKJGQSPMTKB-UHFFFAOYSA-N
InChI=1S/C18H15NO2/c20-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(21)11-7-14/h1-12,18,20-21H
| Molecular Formula | C18H15NO2 |
| Molecular Weight | 277.3172 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Picosulfuric acid (as sodium picosulfate) is a contact laxative, which is used in combination with: magnesium oxide, and anhydrous citric acid for cleansing of the colon as a preparation for colonoscopy in adults. Sodium picosulfate is a prodrug. It has no significant direct physiological effect on the intestine. But it is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: colonic mucosa |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | PREPOPIK Approved UsePREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults. Launch Date2012 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
21.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.3 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
209 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
275 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
7.4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
PubMed
| Title | Date | PubMed |
|---|---|---|
| A review of laxative therapies for treatment of chronic constipation in older adults. | 2010-12 |
|
| Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. | 2010-09 |
|
| Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. | 2010-04 |
|
| Laxative activities of Mareya micrantha (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats. | 2010-02-16 |
|
| A multicentre, observational study of sodium picosulfate and magnesium citrate as a precolonoscopy bowel preparation. | 2009-10 |
|
| Full-laxative versus minimum-laxative fecal-tagging CT colonography using 64-detector row CT: prospective blinded comparison of diagnostic performance, tagging quality, and patient acceptance. | 2009-07 |
|
| Comparison of two common outpatient preparations for colonoscopy in children and youth. | 2009 |
|
| Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. | 2009 |
|
| Commonly used bowel preparations have significant and different effects upon cell proliferation in the colon: a pilot study. | 2008-11-14 |
|
| Changes of intestinal mucosal and plasma PYY in a diarrhea model rat and influence of loperamide as the treatment agent for diarrhea. | 2008-09 |
|
| [Optimization of perioperative management in laparoscopic hernioplasty]. | 2008-09 |
|
| OTC laxative use of sodium picosulfate â results of a pharmacy-based patient survey (cohort study). | 2008-02 |
|
| Comparison of colon-cleansing methods in preparation for colonoscopy--comparative efficacy of solutions of mannitol, sodium picosulfate and monobasic and dibasic sodium phosphates. | 2008 |
|
| Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. | 2007-12-03 |
|
| Interaction between Shaoyao-Gancao-Tang and a laxative with respect to alteration of paeoniflorin metabolism by intestinal bacteria in rats. | 2007-08 |
|
| [Distigmine bromide improves chronic intestinal pseudo-obstruction in a case of MELAS]. | 2007-04 |
|
| Is bowel preparation required before cystoplasty in children? | 2006-10 |
|
| Randomized clinical trial comparing sodium picosulfate with mannitol on the preparation FOR colonoscopy in hospitalized patients. | 2006-07-31 |
|
| Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. | 2006-06 |
|
| Bioavailability of glycyrrhizin from Shaoyao-Gancao-Tang in laxative-treated rats. | 2005-10 |
|
| Screening procedure for detection of stimulant laxatives and/or their metabolites in human urine using gas chromatography-mass spectrometry after enzymatic cleavage of conjugates and extractive methylation. | 2005-04 |
|
| Retrospective study of long-term treatment with sodium picosulfate. | 2004-04 |
|
| Drugs in palliative care: results from a representative survey in Germany. | 2004-03 |
|
| Oral sodium phosphate solution: a review of its use as a colorectal cleanser. | 2004 |
|
| Investigation of the effects of YM-31636, a novel 5-HT3 receptor agonist, on defecation in normal and constipated ferrets. | 2001-07-20 |
|
| Analytical control of a pharmaceutical formulation of sodium picosulfate by capillary zone electrophoresis. | 2001-02-10 |
Sample Use Guides
PREPOPIK ((sodium picosulfate, magnesium oxide, and anhydrous citric acid), supplied as a powder, must be reconstituted with cold water right before its use. There are two dosing regimens, each requires two separate dosing times: The preferred method is the “Split Dose” method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy. The alternative method is the “Day Before” method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy). Additional fluids must be consumed after every dose in both dosing regimens. Instruct patients to consume only clear liquids (no solid food or milk) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy. Instruct patients that if they experience severe bloating, distention, or abdominal pain following the first dose, delay the second dose until their symptoms resolve.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1507649
Sodium picosulfate was biotransformed by intestinal flora that produced a novel sulfotransferase (not sulfatase). The biotransformation was activated by adding phenolic compounds such as phenol, acetaminophen and flavonoids. The enzyme activity related to this biotransformation was the highest in the contents of the caecum region of the intestine. The enzyme activity was 3.0 umole/hr/g wet feces in humans and 0.75 in rats (pH 8.0). The optimal pH was 9.0. The sulfotransferase activity was assayed in reaction mixture consisting of 60 uL of 50 mM PNS (occasionally sodium picosulfate), tyramine and 0.2 ml of the enzyme solution. Sulfatase activity was measured under the assay conditions for he sulfotransferase acitivity without the addition of the acceptor tyramine.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:49 GMT 2025
by
admin
on
Mon Mar 31 18:22:49 GMT 2025
|
| Record UNII |
R09078E41Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175812
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB14232
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
DTXSID20209053
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
69046
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
1074030
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
R09078E41Y
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
1872905
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
603-41-8
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
R09078E41Y
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY | |||
|
210-039-7
Created by
admin on Mon Mar 31 18:22:49 GMT 2025 , Edited by admin on Mon Mar 31 18:22:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY | |||
|
PARENT -> IMPURITY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |